Results from two new studies, including the first randomized controlled trial, are providing further evidence that the antimalaria drug hydroxychloroquine may not help COVID-19 patients.
The two studies, published yesterday in BMJ, found that, when compared with standard treatment, the use of hydroxychloroquine did not increase the likelihood of virus elimination in Chinese patients with mild-to-moderate COVID-19, nor did it have any effect on reducing admissions to intensive care or death in French patients with more severe illness. Both studies also found a higher rate of adverse events in patients treated with the drug.
The authors of both papers conclude that the results do not support the continued use hydroxychloroquine in these patients.
-------------------------------- We are all visitors to this time, this place. We are just passing through. Our purpose here is to observe, to learn, to grow, to love… and then we return home. - Australian Aboriginal proverb
Bazootiehead-in-training
Posts: 37942 | Location: Somewhere in the middle | Registered: 19 January 2010
But the French "scientist" said it worked 100% in his 12 patients (excluding the ones with bad outcomes), and, well, he has thousands of publications (mostly minor, and non-reproducible) and is Soooooo well regarded in France (and thought of as an imperious hack by most of the nation's serious scientists, many of whom will not talk on the record because of how much influence this guy still has there).
Posts: 12539 | Location: Williamsburg, VA | Registered: 19 July 2005
